Navigation Links
Plasma produces KO cocktail for MRSA
Date:11/26/2009

MRSA (methicillin-resistant Staphylococcus Aureus) and other drug-resistant bacteria could face annihilation as low-temperature plasma prototype devices have been developed to offer safe, quick, easy and unfailing bactericidal cocktails.

Two prototype devices have been developed: one for efficient disinfection of healthy skin (e.g. hands and feet) in hospitals and public spaces where bacteria can pose a lethal threat; and another to shoot bacteria-killing agents into infested chronic wounds and enable a quicker healing process.

Two papers published today, Thursday 26 November, as part of a selection of papers on Plasma Medicine in New Journal of Physics (co-owned by the Institute of Physics and German Physical Society), demonstrate how far the design of equipment to harness the bacteria-killing power of low-temperature plasma has come.

Plasma, oft called the fourth state of matter after solid, liquid and gas, is defined by its ionized state. In space, stars are made up of high-energy plasma and, on Earth, it is researchers in high-energy plasma that are making significant strides towards limitless energy from nuclear fusion. The high energy of plasma stems from some atoms or molecules in a gas being stripped of their electrons, resulting in a mix of ionized and neutral species.

Also on Earth, scientists have been working on low-temperature and atmospheric-pressure plasma and have found applications in a range of industries, from plastic bag production to the manufacturing of streetlamps and semiconductor circuits.

In a low-temperature plasma, unlike its high-temperature counterparts, the temperature of ions and neutral particles stays low. The 'recipe' for producing such plasmas is simple: the fraction of atoms (molecules) that are ionized and therefore are hot is so low that collisions with cold neutral atoms (molecules) quickly reduce their temperature again. The analogy of adding a drop of h
'/>"/>

Contact: Joe Winters
joseph.winters@iop.org
44-207-470-4815
Institute of Physics
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
2. How Toxoplasma gondii gets noticed
3. New study shows Dermytol produces pronounced decrease in malignant melanoma tumor volume
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Ethanol byproduct produces green results
6. Obscure fungus produces diesel fuel components
7. Researchers describe implausible chemistry that produces herbicidal compound
8. Wastewater produces electricity and desalinates water
9. UC Davis challenge produces a better air conditioner
10. Accidental discovery produces durable new blue pigment for multiple applications
11. Switchgrass produces biomass efficiently
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... for the first time that coenzyme Q10 offsets the cellular ... drugs - an increased risk of adult-onset diabetes. Statins ... world, able to reduce LDL, or "bad" cholesterol levels, and ... their role in raising the risk of diabetes has only ...
... 10, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ... become a fully reporting public company with the Securities ... many highlights of the filing is a licensing agreement ... PVM International, Inc., has towards the company,s shareholders. The ...
... 2013, New York, NY A dozen Ludwig scientists ... basic and clinical cancer research at this week,s American ... in immunotherapy and epigenetics led the program with important ... "With new immunotherapy agents available to help ...
Cached Biology News:Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 2Medbox Files Form 10 with SEC 2Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR 2
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
(Date:12/19/2014)... Arkansas (PRWEB) December 18, 2014 ... to locate its pilot production facility and future ... develop and produce innovative new materials that safely ... chosen not only because of its historic, strong ... leaders’ efforts to attract leading edge, technology-based companies ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... WALTHAM, Mass. , May 24 Repligen ... of Orphan Products Development of the Food and Drug Administration ... histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ... of marketing exclusivity in the United States if ...
... 24 MO BIO Laboratories, Inc., the leader ... the launch of a groundbreaking new product, PowerLyzer™ 24 ... homogenization and lysis of any biological sample.  The PowerLyzer™ ... analysis faster, minimize cross-contamination, and maintain sample integrity. ...
... CLEVELAND, Ohio , May 24, 2010 Simbionix ... medical professionals and the healthcare industry, is launching,two new hands-on training systems- ... revealed for the first time at,the AUA annual meeting in San ... , ...
Cached Biology Technology:Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3